TrialDiabetes technology & therapeutics2013

Short-term continuous subcutaneous insulin infusion combined with insulin sensitizers rosiglitazone, metformin, or antioxidant α-lipoic acid in patients with newly diagnosed type 2 diabetes mellitus.

Zhimin Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.